News

The phase 2/3 GRANITE-CRC-1L clinical trial has been initiated.

The immunotherapy combination of nivolumab and ipilimumab did not extend progression-free survival in patients with small cell lung cancer when compared with placebo.

Phase 3 study findings show that paclitaxel combined carboplatin stands up to the combination of paclitaxel and ifosfamide for the treatment of patients with uterine carcinosarcoma.

With rusfertide, clinical trial investigators are poised to fill a clinical gap by addressing iron deficiency in patients with polycythemia vera.

A phase 2b study aims to confirm positive efficacy and safety results previously reported with the combination of maveropepimut-S and pembrolizumab in patients with relapsed or refractory diffuse large B-cell lymphoma.

In patients with recurrent and/or metastatic cervical cancer, the second-line combination of balstilimab and zalifrelimab may offer meaningful clinical benefit, but further research is needed.

Mark Roschewski, MD, discusses how different large cell lymphoma subtypes may respond to different therapies.

Although nivolumab did not significantly outperform sorafenib in the CheckMate 459 of patients with advanced hepatocellular carcinoma, positive resuls were shown for the secondary end points.

Results from the phase 2 OCEAN trial show that osimertinib is effective in treating central nervous system metastases from non–small cell lung cancer in patients with certain mutations.

The FDA granted both a regenerative medicine advanced therapy and fast track designation to C-CAR039 for relapsed or refractory diffuse large B-cell lymphoma.

In an interview with Targeted Oncology, Ronald S. Go, MD, discussed the new guidelines for the diagnosis and treatment of histiocytic neoplasms, challenges with managing the disease, and toxicity management.

Richard T. Silver, MD, discusses which patients with myeloproliferative neoplasms may derive the most benefit from recombinant interferon alpha, based on prior research in the chronic myeloid leukemia space and in patients with myeloproliferative neoplasms.

The target number of patients with advanced renal cell carcinoma has been enrolled in the phase 3 CONTACT-3 trial, which aims to determine the efficacy and safety of cabozantinib combined with atezolizumab.

In an interview with Targeted Oncology, Michael Wang, MD, a professor in the department of lymphoma and myeloma at MD Anderson Cancer Center, discussed the safety, efficacy, and tolerability of acalabrutinib plus venetoclax and rituximab in mantle cell lymphoma.

Enobosarm has been granted fast track designation from the FDA and is being explored alone and in combination with abemaciclib in 2 phase 3 clinical trials.

Aspacytarabine for acute myeloid leukemia showed a complete response rate of 37% in phase 2 study.

BNT200 was granted an FDA breakthrough device designation for the treatment of AML-induced depression and anxiety present during the high-intensity induction chemotherapy phase.

Interim results from the phase 3 KEYNOTE-091 show promise for the use of pembrolizumab in patients with stage IB-IIIA non–small cell lung cancer treated in the adjuvant setting.

CA-4948 was found to have a complete remission rate of 40% and an objective response rate of 57% in some patients with acute myeloid leukemia and myelodysplastic syndrome.

Devimistat shows therapeutic potential in patients with clear cell sarcoma after dose-escalation ends with no observed dose-limiting toxicities.

A phase 2 study is preparing to enroll patients with Epstein-Barr virus-positive advanced nasopharyngeal carcinoma, who will be treated with an investigational EBNA1 inhibitor.

Tycel Jovelle Phillips, MD, discussed the use of glofitamab in patients with R/R MCL who have failed BTK inhibitors in an interview with Targeted Oncology.

In an interview with Targeted Oncology, Sunil Sudarshan, MD, discussed the kidney cancer paradigm and opportunities to advance the field with new targets.

Shannon N. Westin, MD, MPH, FACOG, discusses the DUO-E trial, which evaluated durvalumab, a PD-L1 inhibitor, with or without olaparib in patients with endometrial cancer, design, and end points.

American Oncology Network, LLC and its partner, Cancer & Blood Specialists of Arizona have announced the opening of their new cancer center location in Flagstaff, Arizona.

A study of zilovertamab in combination with ibrutinib for the treatment of relapsed or refractory mantle cell lymphoma will be launched in the second quarter of 2022.

Data from a phase 1 trial found that the maximum-tolerated dose of INBRX-106 for metastatic solid tumors is 0.1 mg/kg once every 3 weeks.

Efficacy was seen with blocking LAG-3 in combination with PD-1 as a therapeutic strategy for patients with melanoma. Additionally, this research establishes LAG-3 as the third immune checkpoint pathway to have proven clinical benefit in this patient population.

Telisotuzumab vedotin has shown interim efficacy in patients with advanced or metastatic EGFR wild-type non–small cell lung cancer and has now been granted breakthrough therapy designation from the FDA

Phase 1b data indicate that pembrolizumab in combination with pepinemab is safe for the frontline treatment of advanced, recurrent, or metastatic head and neck squamous cell carcinoma.